Kjell E. Öberg
#130,573
Most Influential Person Now
Kjell E. Öberg's AcademicInfluence.com Rankings
Kjell E. Öbergphilosophy Degrees
Philosophy
#6324
World Rank
#9345
Historical Rank
Logic
#3502
World Rank
#4675
Historical Rank

Download Badge
Philosophy
Kjell E. Öberg's Degrees
- PhD Medical Sciences Uppsala University
- Doctorate Medicine Uppsala University
Why Is Kjell E. Öberg Influential?
(Suggest an Edit or Addition)Kjell E. Öberg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors (2017) (1823)
- Everolimus for advanced pancreatic neuroendocrine tumors. (2011) (1062)
- Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma (1988) (990)
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary (2011) (789)
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (2011) (768)
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site (2016) (758)
- Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (466)
- Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors (2007) (434)
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020) (373)
- ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum (2016) (352)
- Possible induction of systemic lupus erythematosus by interferon‐α treatment in a patient with a malignant carcinoid tumour (1990) (350)
- Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution (2008) (349)
- Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours (2004) (323)
- Tumor Markers in Neuroendocrine Tumors (2000) (288)
- Effect of Surgery on the Outcome of Midgut Carcinoid Disease with Lymph Node and Liver Metastases (2002) (284)
- Malignant Carcinoid Tumors An Analysis of 103 Patients with Regard to Tumor Localization, Hormone Production, and Survival (1987) (283)
- Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors : Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography (2005) (259)
- Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma (2007) (256)
- Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy (2011) (246)
- Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. (2017) (239)
- Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma (2007) (239)
- Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors (1998) (234)
- Long-Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center (2012) (206)
- Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. (2012) (204)
- Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. (2011) (203)
- ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas) (2016) (192)
- Current knowledge on diagnosis and staging of neuroendocrine tumors (2011) (190)
- NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus) (2010) (179)
- Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (172)
- Medical treatment and long‐term survival in a prospective study of 84 patients with endocrine pancreatic tumors (1990) (163)
- Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues (2015) (161)
- Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas (2009) (147)
- Preoperative Diagnosis and Surgical Management of Neuroendocrine Gastroenteropancreatic Tumors: General Recommendations by a Consensus Workshop* (1998) (146)
- Neuroendrocine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients (1990) (131)
- Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) (2004) (121)
- Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids (1998) (116)
- Surgical treatment of mid-gut carcinoid tumors (1990) (116)
- Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors (2013) (116)
- Interferon in the Management of Neuroendocrine GEP-Tumors (2000) (116)
- Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part I—General Overview (2004) (115)
- TREATMENT OF MALIGNANT ENDOCRINE PANCREATIC TUMOURS WITH HUMAN LEUCOCYTE INTERFERON (1986) (113)
- PET in the Diagnosis of Neuroendocrine Tumors (2004) (111)
- Surgery for Asymptomatic Pancreatic Lesion in Multiple Endocrine Neoplasia Type I (1996) (110)
- The Role of PET in Localization of Neuroendocrine and Adrenocortical Tumors (2002) (110)
- Implications for Clinical Practice and Trial Design (2012) (109)
- Octreoscan in patients with bronchial carcinoid tumours (2003) (108)
- Chemotherapy and biotherapy in the treatment of neuroendocrine tumours (2001) (108)
- Imaging of Neuroendocrine Tumors. (2016) (104)
- Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs (2016) (103)
- Pancreatic Endocrine Tumors (2010) (100)
- Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years (2007) (99)
- AUTOIMMUNE THYROID DISEASE IN INTERFERON-TREATED PATIENTS (1985) (97)
- Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. (2017) (93)
- Progression of Metastases and Symptom Improvement from Laparotomy in Midgut Carcinoid Tumors (1996) (90)
- Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatment (1999) (90)
- Neuroendocrine tumours of the pancreas (2000) (87)
- ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
- Autoimmune Phenomena in Patients with Malignant Carcinoid Tumors During Interferon-α Treatment (1991) (86)
- The role of interferons in the management of carcinoid tumours (1991) (83)
- Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography (2005) (83)
- Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin (2007) (83)
- Treatment of malignant endocrine pancreatic tumors with a combination of α-interferon and somatostatin analogs (2002) (81)
- Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part II—Specific NE Tumour Types (2004) (80)
- Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes (1992) (77)
- Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (2010) (77)
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy (2008) (77)
- The genetics of neuroendocrine tumors. (2013) (73)
- Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids (2013) (72)
- Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival (2017) (71)
- Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. (2016) (71)
- Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors (2008) (70)
- Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. (2021) (69)
- ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors (2010) (69)
- A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B (2004) (67)
- ENETS Consensus Guidelines for the Management of Brain, Cardiac and Ovarian Metastases from Neuroendocrine Tumors (2010) (66)
- A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. (2020) (66)
- NETTER-1 Phase III: Progression-Free Survival, Radiographic Response, and Preliminary Overall Survival Results in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate. (2016) (65)
- Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors (2003) (63)
- Gastrointestinal neuroendocrine tumors. (2010) (62)
- Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (2017) (62)
- Pancreatic tumors in multiple endocrine neoplasia type 1: Clinical presentation and surgical treatment (1992) (59)
- Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors (2010) (58)
- Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer (2004) (58)
- Neuroendocrine gastrointestinal tumours (1996) (57)
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study (2020) (57)
- Double-Detargeted Oncolytic Adenovirus Shows Replication Arrest in Liver Cells and Retains Neuroendocrine Cell Killing Ability (2010) (57)
- Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas. (2013) (55)
- Future Aspects of Somatostatin- Receptor-Mediated Therapy (2004) (54)
- Targeted disruption of the mouse phospholipase C β3 gene results in early embryonic lethality (1998) (54)
- Limited Tumor Involvement Found at Multiple Endocrine Neoplasia Type I Pancreatic Exploration: Can It Be Predicted by Preoperative Tumor Localization? (1998) (53)
- Management of functional neuroendocrine tumors of the pancreas. (2018) (51)
- Advances in chemotherapy and biotherapy of endocrine tumors (1998) (49)
- The management of neuroendocrine tumours: current and future medical therapy options. (2012) (49)
- Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. (2014) (48)
- 6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial (2015) (47)
- Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs) (2012) (46)
- Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms (2016) (45)
- Somatostatin analogs for the treatment of neuroendocrine tumors (2011) (44)
- Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment (2002) (44)
- Diagnosis and treatment of carcinoid tumors (2003) (43)
- The Use of Chemotherapy in the Management of Neuroendocrine Tumors (1993) (43)
- A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A (2004) (42)
- Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. (2017) (42)
- A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy (2007) (42)
- Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors (2012) (42)
- Parathyroid surgery in the multiple endocrine neoplasia type I syndrome: Choice of surgical procedure (1986) (42)
- The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells (2012) (41)
- Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role (2015) (41)
- Biomarkers and Molecular Imaging in Gastroenteropancreatic Neuroendocrine Tumors (2011) (41)
- 177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors : Results of the Phase III NETTER-1 Trial (2016) (40)
- Operative tumour yield obviates preoperative pancreatic tumour localization in multiple endocrine neoplasia type 1 (1995) (40)
- Characterization of anti‐interferon‐α antibodies appearing during recombinant interferon‐α2a treatment (1992) (39)
- Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids. (2013) (38)
- Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs (2015) (38)
- PPomas and Nonfunctioning Endocrine Pancreatic Tumors: Clinical Presentation, Diagnosis, and Advances in Management (1994) (37)
- Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors? (2012) (37)
- Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome – An International Consensus Statement (2020) (36)
- Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours (2011) (36)
- Antisera raised against eledoisin and kassinin detect elevated levels of immunoreactive material in plasma and tumor tissues from patients with carcinoid tumors (1984) (35)
- Established Clinical Use of Octreotide and Lanreotide in Oncology (2001) (35)
- Endocrine tumors of the gastrointestinal tract: systemic treatment. (1994) (35)
- The Clinical Use of Interferons in the Management of Neuroendocrine Gastroenteropancreatic Tumors (1994) (35)
- Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial (2015) (34)
- Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue (2009) (34)
- Biotherapies for GEP-NETs. (2012) (33)
- Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors) (2009) (33)
- A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs (2013) (32)
- Liver embolization with trisacryl gelatin microspheres (embosphere) in patients with neuroendocrine tumors (2007) (31)
- Angiography, Computed Tomography, Magnetic Resonance Imaging and Ultrasonography in Detection of Liver Metastases from Endocrine Gastrointestinal Tumours (1987) (31)
- Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. (2020) (31)
- Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells (2011) (31)
- Gene expression in midgut carcinoid tumors: Potential targets for immunotherapy (2005) (30)
- Quality of life in patients with multiple endocrine neoplasia type 1 (MEN1) (2004) (30)
- The action of interferon alpha on human carcinoid tumours. (1992) (30)
- Management of neuroendocrine tumours. (2004) (30)
- Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. (2019) (30)
- Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges (2014) (29)
- Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: Results from the randomized, phase 2 LUNA study (2016) (29)
- NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results. (2016) (29)
- Indication for Liver Transplantation in Young Patients with Small Intestinal NETs Is Rare? (2014) (29)
- The incidence and clinical significance of antibodies to interferon-a in patients with solid tumors (1997) (29)
- Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells (2004) (27)
- Carcinoid tumors, carcinoid syndrome and related disorders (2007) (27)
- CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients (2008) (27)
- SUCCESSFUL TREATMENT OF THERAPY-RESISTANT PANCREATIC CHOLERA WITH HUMAN LEUCOCYTE INTERFERON (1985) (27)
- Neuroendocrine Neoplasms (2011) (26)
- lnterferon-α versus Somatostatin or the Combination of Both in Gastro-Enteropancreatic Tumours (1996) (26)
- Treatment of hormone‐producing adrenocortical cancer with o,p'DDD and streptozocin (1987) (26)
- Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues (2007) (26)
- Regression of a Large Malignant Gastrinoma on Treatment with Sandostatin LAR®: A Case Report (2008) (26)
- Experience with multiple endocrine neoplasia type 1 screening (1995) (25)
- First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. (2018) (24)
- Treatment of the Carcinoid Syndrome with SMS 201-995, a Somatostatin Analogue (1986) (24)
- Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines (2009) (24)
- Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms (2014) (23)
- Neurotensinlike immunoreactivity in plasma and tumor tissue from patients with endocrine tumors of the pancreas and gut (1983) (23)
- 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial) (2015) (23)
- REDUCTION OF GASTRIC HYPERSECRETION IN ZOLLINGER-ELLISON SYNDROME WITH OMEPRAZOLE (1983) (23)
- Somatostatin analog octreotide LAR® in gastro–entero–pancreatic tumors (2009) (23)
- Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours (1995) (21)
- Expression of Growth Factors and Their Receptors in Neuroendocrine Gut and Pancreatic Tumors, and Prognostic Factors for Survival (1994) (21)
- Autoantibodies to epithelial cells in patients on long‐term therapy with leucocyte‐derived interferon‐alpha (IFN‐α) (1990) (20)
- Treatment of neuroendocrine tumors (1994) (19)
- Silver stains for identification of neuroendocrine cells. A study of the chemical background (1990) (19)
- Midgut Carcinoid Tumours (1995) (19)
- Gene Transfer of Vasostatin, a Calreticulin Fragment, into Neuroendocrine Tumor Cells Results in Enhanced Malignant Behavior (2006) (18)
- Rectal neuroendocrine tumors : Diagnosis and treatment (2007) (18)
- Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia. (2012) (18)
- Molecular imaging of neuroendocrine tumors (2008) (18)
- Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment (2005) (17)
- Selective effects of somatostatin analogs on human drug‐metabolizing enzymes (1998) (17)
- Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. (2018) (17)
- Biology, diagnosis, and treatment of neuroendocrine tumors of the gastrointestinal tract. (1994) (17)
- State of the art and future prospects in the management of neuroendocrine tumors. (2000) (16)
- Expression of Tyrosine Kinase Receptors in Lung Carcinoids (2006) (16)
- Decreased survival in patients with CD44‐negative typical bronchial carcinoid tumors (1999) (16)
- Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations (2013) (15)
- PET-Guided Surgery — High Correlation between Positron Emission Tomography with 11C-5-Hydroxytryptophane (5-HTP) and Surgical Findings in Abdominal Neuroendocrine Tumours (2012) (15)
- Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches (2012) (15)
- Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis (2015) (15)
- Nuclear DNA in intestinal carcinoid tumors. A study before and after cytotoxin (streptozotocin and 5‐Fluorouracil) treatment (1985) (15)
- Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR (2005) (15)
- Neuroendocrine gastrointestinal tumours - a condensed overview (1999) (14)
- Improving the Diagnosis and Management of Neuroendocrine Tumors: Utilizing New Advances in Biomarker and Molecular Imaging Science (2013) (14)
- Neuroendocrine gastro-enteropancreatic tumors – from eminence based to evidence-based medicine – A Scandinavian view (2015) (14)
- Diagnosis of Endocrine Gastrointestinal Tumours (1981) (14)
- Interferon Therapy of Malignant Endocrine Pancreatic Tumors1 (1994) (14)
- Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies (2006) (14)
- Identification of Candidate Serum Proteins for Classifying Well-Differentiated Small Intestinal Neuroendocrine Tumors (2013) (14)
- The Genesis of the Neuroendocrine Tumors Concept: From Oberndorfer to 2018. (2018) (13)
- RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe. (2012) (13)
- Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift (2018) (13)
- PROGNOSTIC AND PREDICTIVE VALUE OF CHROMOGRANIN A AND NEURON-SPECIFIC ENOLASE IN PATIENTS (PTS) WITH ADVANCED PANCREATIC NEUROENDOCRINE TUMORS (PNET) TREATED WITH EVEROLIMUS (2010) (13)
- Management of Neuroendocrine Tumors: A Meeting of Experts from Latin America (2008) (13)
- Catecholamine‐Secreting Metastatic Carcinoid as Differential Diagnosis in Pheochromocytoma (2006) (12)
- Roles of miR-196a on gene regulation of neuroendocrine tumor cells (2015) (12)
- Expression and Function of Vinculin in Neuroendocrine Tumors (2007) (12)
- Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs (2002) (12)
- The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR (2007) (12)
- Neuroendocrine tumors: recent progress in diagnosis and treatment. (2011) (12)
- Meal-stimulated and atropine-inhibited secretion of pancreatic polypeptide in healthy subjects, members of MEA I families and patients with malignant endocrine tumours of the gastrointestinal tract (1983) (12)
- Positron emission tomography (PET) with 5-hydroxytryptophan (5-HTP) in the diagnosis and treatment follow upp of carcinoid tumors (1998) (11)
- Erratum: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors (Neuroendocrinology (2004) 80 (394-424)) (2005) (11)
- Gastrointestinal Carcinoid Tumors (Gastrointestinal Neuroendocrine Tumors) and the Carcinoid Syndrome (2010) (11)
- Positron‐Emission Tomography as a Radiological Technique in Neuroendocrine Gastrointestinal Tumors (1994) (10)
- Increased intestinal non‐substance P tachykinin concentrations in malignant midgut carcinoid disease (1999) (10)
- In vivo demonstration of enzyme activity in endocrine pancreatic tumors - decarboxylation of 11C-dopamine. (1996) (10)
- Preoperative Localization of Endocrine Pancreatic Tumours by Intra-Arterial Dynamic Computed Tomography (1990) (10)
- 1. Neuroendocrine Tumors (NETs): Historical Overview and Epidemiology (2010) (10)
- Autoimmunity and Antibodies to Interferons in Patients with Carcinoid Tumors—Clinical Consequences (1994) (10)
- Candidate genes for multiple endocrine neoplasia type 1 (1995) (10)
- A century of advances in neuroendocrine tumor biology and treatment : A tribute to Siegried Oberndorfer (2007) (10)
- Ramsete : a single-arm, multicenter, single-stage phase ii trial of rad001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in europe: analysis by tumor origin (2012) (10)
- Medical Therapy of Gastrointestinal Neuroendocrine Tumors (2017) (10)
- Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. (2019) (9)
- Molecular Genomic Blood Biomarkers for Neuroendocrine Tumors: The Long and Winding Road from Berzelius and Bence Jones to a Neuroendocrine Destination (2020) (9)
- Lung Carcinoids: Long-Term Surgical Results and the Lack of Prognostic Value of Somatostatin Receptors and Other Novel Immunohistochemical Markers (2018) (9)
- Electron-microscopical immunocytochemical study of a pancreatic islet amyloid polypeptidoma (1991) (9)
- The Ultimate Biochemical Diagnosis of Gastro-Enteropancreatic Tumours (1996) (9)
- Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE (2021) (9)
- Management of neuroendocrine tumors: current and future therapies (2011) (8)
- NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE. (2016) (8)
- Suppression of the neoplastic phenotype by transfection of phospholipase C β 3 to neuroendocrine tumor cells (1999) (8)
- Omeprazole inhibits growth of cancer cell line of colonic origin (1995) (8)
- A chromogranin peptide is co-stored with insulin in the human pancreatic islet B-cell granules (1992) (8)
- Dosing of intra-articular triamcinolone hexacetonide for knee synovitis in chronic polyarthritis: a randomized controlled study (2019) (7)
- Antiserum directed against chromogranin A and B (CAB) is a useful marker for peptide hormone-producing endocrine cells and tumors (1992) (7)
- Clinical and biochemical effects in vivo of monoclonal antitumor antibody in verner‐morrison's syndrome (1994) (7)
- Is It Time to Widen the Use of Somatostatin Analogs in Neuroendocrine Tumors (2009) (7)
- In situ hybridization study of chromogranin A and B mRNA in carcinoid tumors (2004) (6)
- Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy (2020) (6)
- ENETS consensus guidelines for synoptic reporting of radiology studies. (2021) (6)
- ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours (2021) (6)
- NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis (2016) (6)
- Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma (2020) (6)
- Somatostatin induces rapid contraction of neuroendocrine cells (2007) (6)
- Peptide hormone markers in endocrine gastrointestinal tumours (1981) (5)
- Efficacy and safety of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analog therapy: Analysis of the ongoing TELESTAR extension period (2016) (5)
- Efficient Human Interferon-α Gene Transfer to Neuroendocrine Tumor Cells with Long-Term and Stable Expression (2006) (5)
- WDHA syndrome caused by a ganglioneuroblastoma producing vasoactive intestinal polypeptide and neuropeptide Y (1986) (5)
- Cardiac Imaging in Carcinoid Heart Disease. (2021) (5)
- Lung and Thymic Neuroendocrine Tumors (2009) (5)
- Multiple endocrine neoplasia 1 (1995) (5)
- Treatment of malignant endocrine pancreatic tumors with a new long-acting somatostatin analogue, SMS 201–995 (1987) (5)
- Molecular cloning and characterization of a cDNA encoding mouse phospholipase C-β3 (1998) (5)
- Efficacy, Safety and Pharmacokinetic Results from a Phase II Study of Pasireotide (SOM230) in the Treatment of Patients with Metastatic NETs Refractory or Resistant to Octreotide LAR (2010) (5)
- Neuroendocrine Gastroenteropancreatic Tumours – Current Views on Diagnosis and Treatment (2005) (5)
- MHC class I and II antigen expression and interferon α treatment of human midgut carcinoid tumors (1994) (5)
- Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome (2017) (5)
- Gastrin-releasing-peptide in neuroendorine tumours (2006) (4)
- Biological Aspects of Neuroendocrine Gastro-Enteropancreatic Tumours (1996) (4)
- Fetal alcohol spectrum disorder: complexity from comorbidity (2016) (4)
- Neuroendocrine tumors and CUP (2012) (4)
- Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors (2018) (4)
- Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis of Small Intestine Neuroendocrine Tumors (2013) (4)
- Selective internal radiation therapy in patients with carcinoid liver metastases (2008) (4)
- Carcinoid and flushing syndromes (2001) (4)
- Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec®) (2010) (4)
- Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study (2021) (4)
- Molecular imaging in diagnosis of neuroendocrine tumours. (2006) (3)
- Clinical presentation, diagnosis, and advances in the management of PPomas and non-functioning endocrine pancreatic tumors. (1995) (3)
- Improved time to quality of life deterioration in patients with progressive midgut neuroendocrine tumors treated with 177Lu-DOTATATE : The NETTER-1 phase III trial (2017) (3)
- Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome (2016) (3)
- Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial (2016) (3)
- Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patients—The ENETS registry. (2018) (3)
- PET for clinical diagnosis and research in neuroendocrine tumors (2003) (3)
- Carcinoid tumors - current considerations (2007) (3)
- Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) versus Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET) : Phase III RADIANT-3 Results (2011) (3)
- Assessing treatment benefit of telotristat etiprate in patients with carcinoid syndrome: Patient exit interviews (2016) (3)
- Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. (2018) (3)
- Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment (2021) (3)
- Universal everolimus for malignant neuroendocrine tumours? (2016) (3)
- Interferon therapy of malignant endocrine pancreatic tumors. In: Endocrine tumors of the pancreas - Recent advances (1995) (3)
- Neoplasms of the Neuroendocrine Pancreas: Insulinoma (2017) (3)
- THE PANCREAS AND GUT (1989) (3)
- 12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. March 11-13, 2015, Barcelona, Spain: Abstracts (2015) (3)
- Expert Review of Endocrinology & Metabolism: major coverage of the advances in an expanding field (2006) (2)
- Interferon Treatment of Neuroendocrine Gut and Pancreatic Tumors (1990) (2)
- Advances in Neuroendocrine Tumor Management (2011) (2)
- Everolimus plus octreotide long-acting release (LAR) for the treatment of advanced neuroendocrine tumors (NET) associated with carcinoid syndrome (RADIANT-2) : Updated overall survival results (2013) (2)
- Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. (2017) (2)
- Neuroendocrine tumor European patient experience: results from the first global NET patient survey - a collaboration between the International Neuroendocrine Cancer Alliance and Novartis (2015) (2)
- Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET) : A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data (2014) (2)
- Does modern treatment of early rheumatoid arthritis reduce the need for intra-articular glucocorticoids? (2013) (2)
- Survival and Clinical Characteristics in 284 Patients with Malignant Midgut Carcinoid Tumors (2007) (2)
- First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial. (2021) (2)
- Interferon Therapy of Neuroendocrine Tumours (1997) (2)
- The Role of Interferons in the Treatment of Solid Tumors (1993) (2)
- Screening for multiple endocrine neoplasia type 1 syndrome (1993) (2)
- Effect of Interferon on T1 Relaxation Times of Liver Metastases from Endocrine Gastrointestinal Tumours (1988) (2)
- Tumor markers in neuroendocrine gastrointestinal tumors (2004) (2)
- Somatostatin receptor scinti-graphy-recent advances concerning imaging of endocrine pancreatic tumors (1993) (2)
- Whole-body 11C-5-HTP-PET as a general imaging technique for detection of Neuroendocrine tumors - a comparison with somatostatin receptor scintigraphy and computed tomography (2003) (2)
- CHAPTER 44 – Neuroendocrine Gastrointestinal and Lung Tumors (Carcinoid Tumors), Carcinoid Syndrome, and Related Disorders (2011) (2)
- Chemical characterization and strategic selection of BFRs for PBT assessment (2004) (1)
- Sandostatin® LAR® Leaders Meeting – European Neuroendocrine Tumour Network ENET (2000) (1)
- Instructions for the preparation of gene mapping reports (1995) (1)
- Olfactory receptor 51E1 is a potential novel tissue biomarker for the diagnosis and prognosis of small intestine neuroendocrine tumors (2012) (1)
- Advances in Pulmonary Neuroendocrine Tumor Management (2013) (1)
- Role of somatostatin analogues in oncology : European Neuroendocrine Tumour Network (ENET), February 24-27, 2000, Innsbruck, Austria/ guest editor, Kjell Oberg (2000) (1)
- Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management : Results from the First Global NET Patient (pt) Survey - A Collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals (2015) (1)
- NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors (2017) (1)
- The Role of Interferons in Neuroendocrine Tumours and Aspects of Mechanisms of Action (1991) (1)
- Treatment of Malignant Neuroendocrine Gut and Pancreatic Tumors with Sandostatin (1989) (1)
- QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors (2018) (1)
- 6571 POSTER Impact of Prior Somatostatin Analog (SSA) Use on PFS in the Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Patients With Advanced Neuroendocrine Tumours (RADIANT-2) (2011) (1)
- Treatment of malignant carcinoid tumors with recombinant interferon alpha-2 (Intron-A) (1987) (1)
- Advances in diagnosing and treating adrenal tumors. (1990) (1)
- Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy (2013) (1)
- Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3) (2011) (1)
- Treatment of neuroendocrine tumours of the gastrointestinal tract (2004) (1)
- XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 1 of 4) (1992) (1)
- HCG‐α and HCG‐β Subunits as Tumour Markers during Therapy in a Case with So‐Called “Non‐Functioning” Islet Cell Tumour (2009) (1)
- Monoclonal antibodies raised against mid-gut carcinoid tumor cells (1990) (1)
- TEMOZOLOMIDE IN PATIENTS WITH METASTATIC BRONCHIAL CARCINOIDS (2011) (1)
- Ultrasound-Guided Biopsies of Neuroendocrine Metastases (1993) (1)
- Interferon Treatment of Neuro-Endocrine Tumors of Pancreas and Gut (1988) (1)
- Circulating microRNA detection in small intestinal neuroendocrine tumor patients treated with somatostatin analogs (2014) (1)
- Consensus Report, 1987 (1987) (1)
- Genetics of Multiple Endocrine Neoplasia Type 1 (1994) (1)
- Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors? (2018) (1)
- Treatment strategies in neuroendocrine tumours (2011) (1)
- Everolimus plus Octreotide LAR versus Placebo plus Octreotide LAR in Patients with Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2) (2011) (1)
- Treatment of high-grade neuroendocrine tumors beyond platinum/etoposide (2014) (1)
- A Multinational Pilot Study on Patients’ Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires (2022) (1)
- Association of weight change with telotristat ethyl in the treatment of carcinoid syndrome. (2017) (1)
- Ectopic ACTH syndrome. An underdiagnosed condition (1997) (1)
- The role of radiopharmaceuticals in diagnosis of neuroendocrine tumors (2006) (0)
- ACTH producing tumour with Cushing syndrome (2017) (0)
- DRAFT: RAMSETE trial of everolimus (RAD001) in the treatment of silent (nonfunctioning) advanced neuroendocrine tumors. (2010) (0)
- Contents Vol. 91, 2010 (2010) (0)
- FRI-14 Modern systemic therapy of neuroendocrine tumors in 2013 (2013) (0)
- Histopathogenesis of mid-gut carcinoids (1987) (0)
- Functional Role of miR-196a in Neuroendocrine Tumor Cells (2015) (0)
- Somatostatin Analogue Therapy of Neuro-Endocrine Gastro-Entero Pancreatic Tumors (2004) (0)
- Summation Session Section II : Neuroendocrine cell biology (2007) (0)
- Neuroendocrine tumors: Preface (2010) (0)
- Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. (2019) (0)
- Editorial - Neuroendocrine tumors A growing cancer field (2011) (0)
- Chemotherapy and biotherapy in neuroendocrine tumors (1993) (0)
- Neuroendocrine tumors A growing cancer field (2011) (0)
- A perspective on the treatment of gastro-entero pancreatic tumors (GEP). Octreotide: The Next Decade (1999) (0)
- Faculty Opinions recommendation of Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011) (0)
- Subject Index Vol. 91, 2010 (2010) (0)
- Faculty Opinions recommendation of Chromogranin A: is it a useful marker of neuroendocrine tumors? (2007) (0)
- The role of the somatostatin analogues (2004) (0)
- Management of metastatic neuroendocrine tumors : Recent advances, Changing trends in the management of NET (2010) (0)
- Chapter 43 – Neuroendocrine Gastrointestinal and Lung Tumors (Carcinoid Tumors), the Carcinoid Syndrome, and Related Disorders (2016) (0)
- Chapter 151 – Carcinoid Syndrome (2016) (0)
- Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl (2017) (0)
- Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges (2014) (0)
- Title Page / Contents (2000) (0)
- Clinical management of neuroendocrine GEP-tumors - Current concepts and future directions (2007) (0)
- Duplex Doppler ultrasound in carcinoid metastases (1991) (0)
- Contents Vol. 82, 2005 (2006) (0)
- Malignant carcinoid tumors — long-term treatment with SMS 201–995 (1987) (0)
- SAT0250 The dosing of intra-articular triamcinolone hexacetonide for knee synovitis in chronic polyarthritis – a randomized controlled study (2018) (0)
- Subject Index Vol. 80, 2004 (2005) (0)
- Negative Lung Carcinoids 2 (2013) (0)
- 363 Production of PP and HCG-a in lung-carcinoids with the carcinoid syndrome (1983) (0)
- 548 PET for visualization of C-11-L-DOPA uptake and decarboxylation in endocrine pancreas cancer (1995) (0)
- Neuroendocrine tumors : New perspection in their therapy (2000) (0)
- Treatment upon Metastatic Pancreatic Nets: Does Chemotherapy Still Play a Role in the Area of Targeting Treatment? (2012) (0)
- Dr. Yao and colleagues reply (2011) (0)
- The secretion of PP in MEA-I members, combined stimulatory and inhibitory test (1983) (0)
- Function of IFN-α gene products in neuroendocrine tumors. (2007) (0)
- Receptor Ligands : Somatostatin analogs (2009) (0)
- Subject Index Vol. 82, 2005 (2006) (0)
- Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. Authors' reply (2004) (0)
- How does PROMID change the treatment landscape of NET (2010) (0)
- MicroRNA Expression in Serum of Small Intestine Neuroendocrine Tumor Patients and miR-196a Biological Function in Neuroendocrine Tumor Cells (2014) (0)
- Workshop 2: Neuroendocrine tumors: Genetics, tumor biology and treatment (2009) (0)
- Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors (2014) (0)
- XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 3 of 4) (1992) (0)
- Algorithm for management of bronchopulmonary neuroendocrine tumors (2013) (0)
- Therapy evaluation of neuroendocrine liver metastases with contrast-enhanced MRI (2004) (0)
- Management of Advanced Small Intestinal Neuroendocrine Tumors (2011) (0)
- Early detection of endocrine pancreatic tumors in men-1 — a clinical benefit of a standardized meal stimulatory test (1987) (0)
- Which therapy for which patient (2011) (0)
- PET imaging in endocrine tumors. In: Diagnostic Nuclear Medicine (1995) (0)
- Microarray Immunoassay Development to Specifically Detect Autoantibodies in Small Intestine Neuroendocrine Tumor (SI-NET) Patients (2013) (0)
- XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 2 of 4) (1992) (0)
- Weight change associated with telotristat ethyl in the treatment of carcinoid syndrome (2017) (0)
- Association of neuroendocrine gastroenteropancreatic tumor disease with multiple endocrine neoplasia type I (1995) (0)
- Best Practice & Research Clinical Gastroenterology (2013) (0)
- Therapy for Metastatic Disease: Bronchi (2018) (0)
- Recent Advances in Diagnosis and Treatment OF Neuroendocrine Gut and Pancreatic Tumors: A meeting held at Kebnekaise, Sweden, June 13-16, 1990 (1991) (0)
- miR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease (2016) (0)
- Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors. (2019) (0)
- Neuroendocrine gut and pancreatic tumors (apudomas). (1995) (0)
- Contents Vol. 101, 2015 (2015) (0)
- Neuroendocrine Gastroenteropancreatic Tumors—Recent Update on Diagnosis and Treatment (2006) (0)
- Transmembrane protein tyrosine phosphatase IA-2 (ICA 512) is expressed in human midgut carcinoids but is not detectable in normal EC cells. (2000) (0)
- Neoplasms of the Neuroendocrine Pancreas: Somatostatinoma (2017) (0)
- B12Global MicroRNA Profiling of Small Intestine Neuroendocrine Tumors (SI-NETs) and Establishment of a Method to Study Serum MicroRNA Expression From the Same Tumors (2013) (0)
- Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0 (2020) (0)
- Multigene liquid biopsy (NETest) is diagnostic of pancreatic and small bowel neuroendocrine tumours and correlates with imaging (2020) (0)
- Neoplastic disorders of the adrenal glands (2006) (0)
- Faculty Opinions recommendation of Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. (2008) (0)
- IN-111-OCTREOTIDE SCINTIGRAPHY IN MALIGNANT CARCINOID TUMOURS (1994) (0)
- Thyroid Autoimmunity Induced by Interferon Therapy (1991) (0)
- Unblocking Bottlenecks: Gastrointestinal and Lung Neuroendocrine Tumors Early Detection (2013) (0)
- XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 4 of 4) (1992) (0)
- patients with advanced neuroendocrine tumors refractory or resistant to (2012) (0)
- The somatostatin analogue PTR-3173, a backbone cyclic peptide with effect on growth hormone but not insulin secretion (2000) (0)
- Expression of somatostatin receptor subtypes 1-5 in malignant endocrine pancreatic tumors (2002) (0)
- Predicting responses to interferon (1990) (0)
- Circulating Biomarkers in Neuroendocrine Tumours (2015) (0)
- ENETS Newsletter Summer/Fall 2013 (2013) (0)
- Roles of somatostatin analogues in oncology (2000) (0)
- Societies and Guidelines for Neuroendocrine Tumors (2015) (0)
- Editorial (2000) (0)
- Chapter 6, Diagnostic pathways : (2010) (0)
- Chairperson's Introduction (2009) (0)
- Expression of c-Kit, phospho-c-kit, PDGFRβ and absence of c-Kit mutation in exon 11 in adrenocortical cancer (2004) (0)
- Chromogranin a — a marker for neuroendocrine tumors (1987) (0)
- The Carcinoid Syndrome (1973) (0)
- Business Briefing : European oncology review (2005) (0)
- Rationale for Combining mTOR with other Targeted Agents in the Treatment of Neuroendocrine Tumors (2010) (0)
- Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET) : A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data (2015) (0)
- Faculty Opinions recommendation of Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. (2011) (0)
- PREDICTING RESPONSES TO INTERFERON. REPLY (1990) (0)
- ENETS News Letter (2015) (0)
- Contents Vol. 100, 2014 (2015) (0)
- Chromogranin A and B in Hirschsprung's disease (1993) (0)
- Contents Vol. 80, 2004 (2005) (0)
- Small intestine and carcinoid tumours. (2002) (0)
- Section Introduction: Emergent Management of Neuroendocrine Tumors (2014) (0)
- Nordic and North American neuro endocrine tumor management : A clinical and scientific synopsis (2008) (0)
- Chromogranin in endocrine cells and carcinoids of small intestine (1987) (0)
- Neuroendocr ine Gas t roenteropancreat i c Tumors — Recent Update on Diagnos i s and Treatment (2006) (0)
- Interferon: Does it still play a role? (2007) (0)
- Neoplasms of the Neuroendocrine Pancreas: ACTH producing with Cushing syndrome (2017) (0)
- Paraneoplastic Antigen Ma2 (PNMA2) Auto-Antibodies as Biomarkers for Early Small Intestine Neuroendocrine Tumors Detection (2010) (0)
- A meta-analysis of the accuracy of a neuroendocrine tumor mRNA biomarker (NETest) in the blood. (2020) (0)
- Neuroendocrine tumours : Preface (2007) (0)
- Neuroendocrine tumors - new perspection in their therapy. In: Advances in Pancreatic Disease (1999) (0)
- Neuroendocrine Gut and Pancreatic Tumors Recent Advances in Diagnosis and Treatment a meeting held at Lofoten, Norway, June 24-28, 1992 (1993) (0)
- Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) : A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS) (2014) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kjell E. Öberg?
Kjell E. Öberg is affiliated with the following schools: